Biodesix is a diagnostics & research business based in the US. Biodesix shares (BDSX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.47 – a decrease of 11.41% over the previous week. Biodesix employs 273 staff and has a trailing 12-month revenue of around $71.3 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.47 |
|---|---|
| 52-week range | $0.45 - $2.04 |
| 50-day moving average | $0.68 |
| 200-day moving average | $1.28 |
| Wall St. target price | $2.90 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.33 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.518 from 2025-05-02
| 1 week (2025-04-29) | -3.25% |
|---|---|
| 1 month (2025-04-04) | -9.19% |
| 3 months (2025-02-06) | -50.19% |
| 6 months (2024-11-06) | -61.05% |
| 1 year (2024-05-06) | -65.92% |
|---|---|
| 2 years (2023-05-05) | -68.02% |
| 3 years (2022-05-05) | 2.12 |
| 5 years (2020-05-02) | N/A |
| Revenue TTM | $71.3 million |
|---|---|
| Gross profit TTM | $55.8 million |
| Return on assets TTM | -21.81% |
| Return on equity TTM | -337.3% |
| Profit margin | -60.19% |
| Book value | $0.14 |
| Market Capitalization | $75.6 million |
TTM: trailing 12 months
We're not expecting Biodesix to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Biodesix's shares have ranged in value from as little as $0.45 up to $2.04. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biodesix's is 1.159. This would suggest that Biodesix's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
To put Biodesix's beta into context you can compare it against those of similar companies.
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development, and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Some of the best stock trading apps for beginners include SoFi, Robinhood, Public, Stash, Opto and more. Compare your options here.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2025 according to Finder’s comprehensive review.
Compare the 7 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
Fidelity is best for its extensive tools and resources, while Robinhood is a popular choice for its simple, easy-to-use platform.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .